NEW YORK (Reuters Health)—The early elevation in intact parathyroid hormone (iPTH) seen with denosumab treatment is not associated with increased bone formation, according to research from Eli Lilly and Company.
Denosumab is a member of the anticatabolic/antiresorptive class of drugs used to treat osteoporosis; iPTH levels are increased in the first several months after denosumab administration, suggesting the possibility that it could increase early bone formation, researchers say.
Dr. David W. Dempster from Columbia University, New York, and colleagues characterized denosumab-induced changes in iPTH levels in conjunction with bone histomorphometric indices and bone turnover markers and compared these effects with those induced by the anabolic agent teriparatide (an analog of PTH).
Their open-label, randomized study included 69 postmenopausal women with osteoporosis, and the primary endpoint was the change from baseline to three months in mineralizing surface/bone surface (MS/BS) in the cancellous envelope of transiliac bone biopsies. MS/BS, they say, readily distinguishes between anabolic and antiresorptive mechanisms of action.
| | | Next → | Single Page